Aurora kinase inhibitor-3

Cat. No.: HY-112373

CAS No.: 879127-16-9

Molecular Formula: $C_{21}H_{18}F_3N_5O$

Molecular Weight: 413.4

Target: Aurora Kinase

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (302.37 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.4190 mL	12.0948 mL	24.1896 mL
5 mM	0.4838 mL	2.4190 mL	4.8379 mL
10 mM	0.2419 mL	1.2095 mL	2.4190 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.03 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (5.03 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.03 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC_{50} of 42 nM, and weakly inhibits EGFR with an IC_{50} of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket[1].

IC_{50} & Target

Aurora A
42 nM (IC_{50})

REFERENCES

[1]. Tari LW, et al. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinitydisubstituted pyrimidine inhibitors. Bioorg Med Chem Lett. 2007 Feb 1;17(3):688-91.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA